Loading…
Novavax, Inc. is projected to rise to $11.80 by 2027, a +27% move from its current price of $9.33. NVAX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $9.06 | $9.33 | $9.61 | +0.03% |
| Jul 14 | $8.96 | $9.34 | $9.73 | +0.06% |
| Jul 15 | $8.88 | $9.34 | $9.82 | +0.09% |
| Jul 16 | $8.81 | $9.34 | $9.90 | +0.12% |
| Jul 17 | $8.75 | $9.34 | $9.98 | +0.15% |
| Jul 18 | $8.70 | $9.35 | $10.04 | +0.18% |
| Jul 19 | $8.65 | $9.35 | $10.10 | +0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.65 | $9.35 | $10.10 | +0.21% |
| Week 2 | $8.40 | $9.37 | $10.45 | +0.42% |
| Week 3 | $8.21 | $9.39 | $10.74 | +0.62% |
| Week 4 | $8.06 | $9.41 | $10.98 | +0.83% |
| Week 5 | $7.93 | $9.43 | $11.21 | +1.04% |
| Week 6 | $7.82 | $9.45 | $11.42 | +1.25% |
| Week 7 | $7.71 | $9.47 | $11.62 | +1.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Novavax, Inc. is a biotechnology company that engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax, Inc. (NVAX) is trading at $9.36 per share, with a market capitalization of $1.54B, and a rank of 2144. The current price is complemented by a 30-day range that reflects potential near-term movement.
The asset’s price outlook from the provided forecast shows a path of gradual renewal in value across years, with the 2026 average price at $9.36 and continued gains in subsequent years. By 2050, the forecasted average price reaches $88.56, with substantial upside in the max forecasts along the way.
A major floor 22.7% below — a decisive break under it would weaken the trend.
The nearest floor, 8.3% below — buyers have tended to step in here.
The nearest ceiling, 17.6% above — a clean break opens room to run.
A major ceiling 28.9% above — clearing it would confirm fresh momentum.
Key NVAX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NVAX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.38 | Sell | $9.37 | Sell |
| MA 10 | $9.38 | Sell | $9.34 | Sell |
| MA 20 | $9.21 | Buy | $9.31 | Buy |
| MA 50 | $9.29 | Buy | $9.23 | Buy |
| MA 100 | $9.21 | Buy | $9.04 | Buy |
| MA 200 | $8.54 | Buy | $8.73 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.56 | Neutral |
| Stoch RSI (14) | 59.29 | Neutral |
| CCI (20) | 35.49 | Neutral |
| Williams %R (14) | -34.75 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 3.67 | Buy |
| Bollinger %B (20,2) | 0.61 | Neutral |
| Stochastic %K (14) | 65.25 | Neutral |
| TRIX (15) | -0.02 | Sell |
| Awesome (5,34) | -0.08 | Sell |
| Ultimate (7,14,28) | 46.93 | Neutral |
| Momentum (10) | 0.77 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 9.35 | Sell |
| ADX (14) | 8.24 | Neutral |
| ATR (14) | 0.23 | Info |
The 30-day technical picture is bullish. RSI14 sits at 50, and the price is trading above both the SMA50 of $9.11 and the SMA200 of $8.50. Key near-term levels include support at $8.56 and resistance at $11.09, with the 30-day price range spanning $7.41 to $11.82. Annualized volatility stands at 70%, signaling notable price variability over the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.13 | $9.33 | $12.54 | 0% | Neutral | |
| $9.33 | $11.80 | $15.83 | +27% | Bullish | |
| $10.38 | $13.53 | $18.87 | +45% | Bullish | |
| $11.92 | $15.93 | $22.90 | +71% | Bullish | |
| $12.73 | $17.40 | $25.66 | +86% | Bullish | |
| $12.10 | $16.87 | $25.45 | +81% | Bullish | |
| $12.90 | $18.33 | $28.21 | +96% | Bullish | |
| $13.24 | $19.14 | $30.00 | +105% | Bullish | |
| $14.60 | $21.47 | $34.22 | +130% | Bullish | |
| $18.28 | $27.31 | $44.21 | +193% | Bullish | |
| $19.77 | $31.80 | $54.92 | +241% | Bullish | |
| $40.66 | $74.28 | $140.95 | +696% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.13 | $9.33 | $11.01 | +0.00% |
| August 2026 | $8.01 | $9.47 | $11.51 | +1.49% |
| September 2026 | $8.05 | $9.59 | $11.79 | +1.23% |
| October 2026 | $7.82 | $9.38 | $11.65 | -2.16% |
| November 2026 | $7.90 | $9.53 | $11.94 | +1.60% |
| December 2026 | $8.20 | $9.93 | $12.54 | +4.22% |
Click any year to see its month-by-month NVAX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, NVAX is projected to trade between $7.13 and $12.54, averaging $9.33 — a potential gain of 0% from today's $9.33. Price action looks broadly range-bound.
Novavax, Inc.'s 2027 outlook centres on $11.80, within a $9.33 to $15.83 range. That is up +26% on the projected 2026 average. That marks a +27% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, NVAX could reach as high as $18.87, with a base case around $13.53 and support toward $10.38 — roughly +45% from $9.33. Momentum favours further upside here.
Expect NVAX to range from $11.92 to $22.90 through 2029. The $15.93 average target implies a +71% move from current prices. That is up +18% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The NVAX price prediction for 2030 points to an average of $17.40 (low $12.73, high $25.66) — a potential gain of +86% on today's $9.33. Momentum favours further upside here.
In 2031, NVAX is projected to trade between $12.10 and $25.45, averaging $16.87 — a potential gain of +81% from today's $9.33. That is -3% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
Novavax, Inc.'s 2032 outlook centres on $18.33, within a $12.90 to $28.21 range. That is up +9% on the projected 2031 average. That marks a +96% change versus current levels. Momentum favours further upside here.
By 2033, NVAX could reach as high as $30.00, with a base case around $19.14 and support toward $13.24 — roughly +105% from $9.33. Buyers look set to stay in control over this stretch.
Expect NVAX to range from $14.60 to $34.22 through 2034. The $21.47 average target implies a +130% move from current prices. That is up +12% on the projected 2033 average. Momentum favours further upside here.
The NVAX price prediction for 2035 points to an average of $27.31 (low $18.28, high $44.21) — a potential gain of +193% on today's $9.33. Buyers look set to stay in control over this stretch.
In 2040, NVAX is projected to trade between $19.77 and $54.92, averaging $31.80 — a potential gain of +241% from today's $9.33. That is up +16% on the projected 2035 average. Momentum favours further upside here.
Novavax, Inc.'s 2050 outlook centres on $74.28, within a $40.66 to $140.95 range. That is up +134% on the projected 2040 average. That marks a +696% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in NVAX today (≈ 107.181136 NVAX) could be worth
$7,961.85
+$6,961.85 (+696%) by 2050 · US Dollar
Based on the average projected NVAX price of $74.28 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NVAXwould be worth at today's price.
$1,000 invested in NVAX on Jul 10, 2025 (≈ 140.845072 NVAX) would be worth
$1,314.08
+$314.08 (+31.4%) today · 1.31× · US Dollar
Based on a NVAX entry price of $7.1 vs. today's $9.33.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.74 | $957.91 | -4.2% |
| 1 month ago | $8.56 | $1,089.95 | +9.0% |
| 3 months ago | $8.12 | $1,149.01 | +14.9% |
| 6 months ago | $7.75 | $1,203.87 | +20.4% |
| 1 year ago | $7.1 | $1,314.08 | +31.4% |
| All time (5.0y) ago | $184.18 | $50.66 | -94.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NVAX forecast.
Our base-case forecast reaches $19.00 around 2033.
Implied market cap at $19.00: $3.12B
In the multi-year view, the forecast shows bullish sentiment from 2027 onward, with 2026 labeled as Neutral. The average price climbs from $9.36 in 2026 to $18.94 by 2030 (ROI 102.4%), then to $31.58 by 2035 (ROI 237.3%), and to $36.43 by 2040 (ROI 289.2%). By 2050, the average forecast price is $88.56 with an ROI of 846.1%, and sentiment remains bullish.
These figures illustrate a strong long-run upward trajectory, though actual outcomes are not guaranteed and depend on market conditions and other factors.
Tap a question to reveal the answer.
Avg $18.94; min $13.31; max $29.22; ROI 102.4%; sentiment BULLISH.
The forecast shows a bullish sentiment from 2027 onward with rising averages to 2030 ($18.94) and beyond, including an ROI of 102.4% by 2030, 289.2% by 2040, and 846.1% by 2050, while 2026 is Neutral.
2035 max $54.16; avg $31.58; ROI 237.3%.
Current price $9.36; market cap $1.54B.
RSI14 is 50; SMA50 is $9.11; SMA200 is $8.50; support $8.56; resistance $11.09; 30-day range $7.41–$11.82.
Novavax, Inc. Community Discussion
0Share your Novavax, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.